Hailong Hu

7PUBLICATIONS
34CO-AUTHORS
Predictive and prognostic markersMedical devicesCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 24, 2026
Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel.

|Mar 26, 2026
Cost-Effectiveness of Circulating Tumor DNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Based on IMvigor011 Trial.

Zihan Xue, Yunkai Qie, Shan Liang

|Dec 25, 2025
Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.

Zihan Xue, Yunkai Qie, Chong Shen

|Jan 08, 2025
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High-Risk Non-Muscle-Invasive Bladder Cancer.

Yunkai Qie, Shiwang Huang, Chong Shen

|Apr 07, 2023
circSOBP Inhibits Bladder Cancer Proliferation and Metastasis by Regulating the miR-200a-3p/PTEN Axis and Participating in the Immune Response.

Yinglang Zhang, Zhi Li, Yu Zhang

|Mar 23, 2023
Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study.

Ruopeng Su, Zeyu Chen, Daoping Hong

Pageof 2

Frequent Collaborators

3 joint publications

Zhouliang Wu

2 joint publications

Dawei Tian

2 joint publications

Yunkai Qie

2 joint publications

Zihan Xue